Loading…
Employees: 10,900
Size AdaptHealth (AHCO) is a United States Health Care company (Medical/Nursing Services) with a market value of $1.00B, the 2245th largest of 3,117 United States companies the cockpit tracks. Shares closed at $10.83 on 6 Nov 2026.
Performance Over six months the shares gained 7.8%, against +4.8% for the median peer and -1.1% for the United States market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue fell 3.2% over the last twelve months (peer median +6.7%); the operating margin is 3.2% (peer median 7.9%).
Valuation It trades at 0.9× enterprise value to sales against a peer median of 1.8× (4th cheapest of 21).
Price implies For today's price to make sense, revenue must grow about 16% a year for seven years (Req g). Recent delivered growth is +25%, so the hurdle is -9 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 4.9 points below its cost of capital (7.5% WACC).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $3.15B | $3.24B | $3.26B | $3.20B | $2.97B |
| Revenue growth | — | 0% | +2% | +8% | — |
| Gross profit | $468M | $569M | $636M | $422M | $353M |
| EBITDA | $586M | $636M | $704M | $661M | $620M |
| Net income | -$404M | -$70.8M | $82.7M | -$679M | $69.3M |
| Free cash flow | $81.9M | $219M | $236M | $143M | -$17.6M |
| Capital expenditure | $497M | $382M | $306M | $337M | $391M |
| Total debt | $2.05B | $1.90B | $2.13B | $2.29B | $2.33B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AHCO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.7% | +2.6% | 10th lowest of 21 |
| 6-month return | +7.8% | +4.8% | 10th highest of 20 |
| Distance from 52-week high | -19.4% | -20.4% | 9th highest of 21 |
| Revenue growth (TTM) | -3.2% | +6.7% | 5th lowest of 21 |
| Operating margin | 3.2% | 7.9% | 5th lowest of 21 |
| EV / Sales | 0.9× | 1.8× | 4th cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | 16.3% | 9.1% | 7th most demanding of 18 |
| Growth delivered (Del g) | +25.2% | +10.9% | 3rd highest of 18 |
| Hurdle (Req g minus delivered) | -8.8 pp | +0.2 pp | 8th least demanding of 18 |
| ROIC minus cost of capital | -4.9 pp | -2.2 pp | 5th lowest of 20 |
| EV / EBITDA | 5.1× | 10.1× | 4th cheapest of 17 |
| Net debt / EBITDA | 3.4× | 2.6× | 8th most indebted of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| AdaptHealth AHCO | United States | $1.00B | +8% | -3% | 3% | 0.9× | 16.3% | +25.2% |
| Regis Healthcare REG.AX | Australia | $1.05B | -17% | +17% | 4% | 1.0× | 14.6% | +14.4% |
| BML 4694.T | Japan | $887M | -2% | +4% | 7% | 0.6× | -9.7% | +1.6% |
| Terveystalo Oy TTALO.HE | Finland | $883M | -19% | -8% | 8% | 1.2× | -4.6% | +5.3% |
| Novogene 688315.SS | China | $1.16B | +31% | +6% | 7% | 2.6× | 17.1% | +8.2% |
| GoodRx GDRX | United States | $1.20B | +20% | -2% | 12% | 1.8× | 6.8% | +7.7% |
| Thyrocare Technologies THYROCARE.NS | India | $830M | +5% | +22% | 26% | 8.3× | 27.9% | +10.9% |
| Nutex Health NUTX | United States | $1.24B | +32% | +7% | 43% | 1.8× | -19.5% | +253.5% |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +12% | +20% | 18% | 6.6× | 32.4% | +10.5% |
| Jinxin Fertility 1951.HK | Hong Kong | $800M | -2% | +7% | 11% | 2.9× | 18.0% | +12.4% |
| Pennant PNTG | United States | $1.27B | +1% | +38% | 6% | 1.6× | 21.1% | +19.4% |
| Lumexa Imaging LMRI | United States | $1.29B | +29% | +8% | 3% | 2.1× | n/a | n/a |
| OPKO Health OPK | United States | $1.29B | +52% | -11% | -29% | 2.4× | n/a | n/a |
| Diagnostyka DIA.WA | Poland | $1.29B | -5% | +19% | 15% | 2.4× | 6.9% | +18.9% |
| Ginkgo Bioworks DNA | United States | $760M | +26% | -52% | -258% | 7.7× | n/a | n/a |
| WELL Health Technologies WELL.TO | Canada | $760M | -5% | +39% | 7% | 1.4× | 9.1% | +94.5% |
| HK inno.N 195940.KS | South Korea | $745M | -32% | +7% | 12% | 0.9× | -10.8% | +12.2% |
| H.U.Group 4544.T | Japan | $1.35B | +24% | +1% | 2% | 0.9× | 10.1% | +2.1% |
| Clariane CLARI.PA | France | $1.40B | -20% | +1% | 6% | 1.6× | 6.7% | +6.5% |
| U.S. Physical Therapy USPH | United States | $1.48B | +68% | +11% | 10% | 2.7× | 19.9% | +13.0% |
| GMR Solutions GMRS | United States | $672M | n/a | -4% | 14% | 0.9× | -20.0% | -4.0% |